You are currently viewing our desktop site, do you want to download our app instead?
Moneyweb Android App Moneyweb iOS App Moneyweb Mobile Web App

NEW SENS search and JSE share prices

More about the app

Aspen gets unsolicited offers for pharma ingredient unit

The approaches are for operations almost exclusively in Europe and make both chemicals and the anticoagulant drug heparin.
Image: Supplied

Aspen Pharmacare Holdings has received two unsolicited offers for its active pharmaceutical ingredient business and will start a process aimed at evaluating proposals for the unit.

The approaches are for operations almost exclusively in Europe and make both chemicals and the anticoagulant drug heparin, Chief Executive Officer Stephen Saad said by phone Thursday. The company has has already sold most of its other heparin interests, part of a recent slimming down effort to reduce debt.

Moneyweb Insider INSIDERGOLD

Subscribe for full access to all our share and unit trust data tools, our award-winning articles, and support quality journalism in the process.

Choose an option:

R63 per month
R630 per year SAVE R126

You will be redirected to a checkout page.
To view all features and options, click here.

A monthly subscription is charged pro rata, based on the day of purchase. This is non-refundable and includes a R5 once-off sign-up fee.
A yearly subscription is refundable within 14 days of purchase and includes a 365-day membership.

Click here for more information.

“We had unsolicited offers that given their materiality we have to consider,” Saad said. Africa’s largest drugmaker has started “a structured process” to facilitate any proposal for the division, according to an earlier statement.

The shares, which have climbed 44% in the last year, were 1.7% higher at 11:35 a.m. in Johannesburg.

The disposal of an infant-formula business to Lactalis International and a Japanese unit to Novartis AG in 2019 helped the drugmaker reduce borrowings, as did the agreed sale of its European thrombosis division to US drugmaker Mylan NV in 2020.

Aspen has switched focus to producing so-called steriles such as anesthetics rather than lower-value generic medicines, paving the way for a push into vaccines. The group has a contract to fill and package Johnson & Johnson’s Covid-19 dose in South Africa, and is in talks with the US company about gaining a license.

The Durban, South Africa-based company may still consider building a plant to make the ingredients needed for that vaccine, but it would be near its manufacturing site in the country, Saad said.

© 2021 Bloomberg

COMMENTS   2

Sort by:
  • Oldest first
  • Newest first
  • Top voted

You must be signed in to comment.

SIGN IN SIGN UP

GREAT! to See Aspen on Nitro’s … we rocketing to 400+ easy in 6 months
Initial target R244.

Viceroy report on Aspen was poor. Viceroy received a R50 Mill fine for the report on Capitec. Viceroy not credible, unnecessarily destroy shareholder capital in Aspen.

Stephen SAAD managed debt well since that report.
Covid is here to stay… Manufacturing the Vaccine is a positive.
Lets Pump Aspen!

The way Aspen is moving currently…. @221…. horizontal line forming….may go up to R244 … much quicker.

End of comments.

LATEST CURRENCIES  

USD / ZAR
GBP / ZAR
EUR / ZAR
BTC / USD

Podcasts

INSIDER SUBSCRIPTIONS APP VIDEOS RADIO / LISTEN LIVE SHOP OFFERS WEBINARS NEWSLETTERS TRENDING PORTFOLIO TOOL CPD HUB

Follow us:

Search Articles:
Click a Company: